Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hizentra (IgPro20) for CIDP Maintenance (PATH)
NCT01545076Phase 3Completed
- Sponsor
- CSL Limited
- Start
- Mar 2012
- Primary completion
- Sep 2016
- Modality
- Biologic
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of IgPro10 in chronic inflammatory demyelinating polyneuropathy (CIDP) (3 arms), sponsored by CSL Limited. Primary endpoint: Percentage of Subjects With CIDP Relapse or Are Withdrawn for Any Other Reason at 25 weeks. Started Mar 2012; status: completed.
02
Drugs
IgPro10
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT01545076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01545076.